Unknown

Dataset Information

0

Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy.


ABSTRACT: The adoptive transfer of chimeric antigen receptor (CAR) T cells represents a breakthrough in clinical oncology, yet both between- and within-patient differences in autologously derived T cells are a major contributor to therapy failure. To interrogate the molecular determinants of clinical CAR T-cell persistence, we extensively characterized the premanufacture T cells of 71 patients with B-cell malignancies on trial to receive anti-CD19 CAR T-cell therapy. We performed RNA-sequencing analysis on sorted T-cell subsets from all 71 patients, followed by paired Cellular Indexing of Transcriptomes and Epitopes (CITE) sequencing and single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) on T cells from six of these patients. We found that chronic IFN signaling regulated by IRF7 was associated with poor CAR T-cell persistence across T-cell subsets, and that the TCF7 regulon not only associates with the favorable naïve T-cell state, but is maintained in effector T cells among patients with long-term CAR T-cell persistence. These findings provide key insights into the underlying molecular determinants of clinical CAR T-cell function. SIGNIFICANCE: To improve clinical outcomes for CAR T-cell therapy, there is a need to understand the molecular determinants of CAR T-cell persistence. These data represent the largest clinically annotated molecular atlas in CAR T-cell therapy to date, and significantly advance our understanding of the mechanisms underlying therapeutic efficacy.This article is highlighted in the In This Issue feature, p. 2113.

SUBMITTER: Chen GM 

PROVIDER: S-EPMC8419030 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy.

Chen Gregory M GM   Chen Changya C   Das Rajat K RK   Gao Peng P   Chen Chia-Hui CH   Bandyopadhyay Shovik S   Ding Yang-Yang YY   Uzun Yasin Y   Yu Wenbao W   Zhu Qin Q   Myers Regina M RM   Grupp Stephan A SA   Barrett David M DM   Tan Kai K  

Cancer discovery 20210405 9


The adoptive transfer of chimeric antigen receptor (CAR) T cells represents a breakthrough in clinical oncology, yet both between- and within-patient differences in autologously derived T cells are a major contributor to therapy failure. To interrogate the molecular determinants of clinical CAR T-cell persistence, we extensively characterized the premanufacture T cells of 71 patients with B-cell malignancies on trial to receive anti-CD19 CAR T-cell therapy. We performed RNA-sequencing analysis o  ...[more]

Similar Datasets

| S-EPMC10196916 | biostudies-literature
| S-EPMC7520174 | biostudies-literature
| S-EPMC2812489 | biostudies-other
| S-EPMC7260017 | biostudies-literature
| S-EPMC8509430 | biostudies-literature
2020-02-11 | GSE145007 | GEO
| S-EPMC7080275 | biostudies-literature
| S-EPMC8361834 | biostudies-literature
| S-EPMC8779849 | biostudies-literature
| S-EPMC4357816 | biostudies-literature